A treatment that works for all patients, not just the fortunate few
Each year, two million newborns enter the world only to have their brains deprived of oxygen in the first moments of life — a condition that kills many and leaves survivors with profound disability, yet has resisted meaningful treatment for decades. Now, a team of Spanish researchers in Madrid is exploring whether cannabidiol, administered orally within the first eighteen hours of life, might do what no existing therapy can: reach every child, in every corner of the world, and interrupt the cellular destruction before it becomes permanent. The work is early, but the question it asks is ancient — how do we protect the most vulnerable lives at the moment they are most exposed?
- Dos millones de recién nacidos sufren cada año una lesión cerebral por falta de oxígeno al nacer, y la mayoría del mundo no tiene acceso a ningún tratamiento eficaz.
- La única terapia existente —el enfriamiento corporal— exige tecnología avanzada, personal especializado y actuar en menos de seis horas, condiciones imposibles en gran parte del planeta.
- El equipo del doctor Martínez Orgado en el Hospital Clínico San Carlos trabaja contra ese reloj con una solución oral de cannabidiol que ampliaría la ventana de tratamiento a dieciocho horas.
- Los modelos animales ya sugieren que el CBD puede actuar como antiinflamatorio y antioxidante, interrumpiendo la cascada de daño neuronal que sigue a la privación de oxígeno.
- Si los ensayos de seguridad avanzan, el tratamiento podría llegar también a prematuros y a familias en entornos de bajos recursos, poblaciones hoy completamente excluidas de cualquier opción terapéutica.
Cada año, aproximadamente dos millones de recién nacidos sufren en sus primeros instantes de vida una privación de oxígeno y flujo sanguíneo en el cerebro. La encefalopatía hipóxico-isquémica neonatal mata a algunos de ellos; a quienes sobreviven, a menudo los condena a una discapacidad neurológica severa y permanente. Durante décadas, la medicina ha tenido muy poco que ofrecer.
El único tratamiento disponible es la hipotermia terapéutica, que consiste en enfriar el cuerpo del bebé para frenar el daño metabólico. Sus limitaciones son brutales: solo funciona en recién nacidos a término con casos moderados o graves, debe aplicarse en las primeras seis horas de vida y requiere infraestructura hospitalaria sofisticada. En gran parte del mundo, donde los partos ocurren en clínicas rurales o en domicilios, esta opción sencillamente no existe. Los prematuros, ya de por sí frágiles, quedan excluidos por completo.
Un equipo del Hospital Clínico San Carlos de Madrid, liderado por José Martínez Orgado, está explorando un camino distinto: una formulación oral de cannabidiol —el compuesto no psicoactivo del cannabis— como tratamiento para la lesión cerebral neonatal. A diferencia del enfriamiento, el CBD no buscaría frenar el daño sino revertir la cascada de destrucción celular que sigue a la falta de oxígeno, con una ventana de administración de hasta dieciocho horas tras el nacimiento.
Los modelos animales ya han mostrado que el CBD actúa como potente antiinflamatorio y antioxidante, dos mecanismos capaces de interrumpir esa reacción en cadena. Ahora el equipo trabaja en desarrollar una solución oral apta para neonatos, y el siguiente paso es establecer la seguridad y la dosis correcta antes de pasar a ensayos en humanos.
Lo que hace transformador este enfoque es su alcance: no requeriría equipos especializados ni personal altamente entrenado, podría administrarse en cualquier entorno y cubriría también a prematuros de más de 33 semanas, hoy excluidos de toda terapia. La ambición del equipo es explícita: un tratamiento para todos los pacientes, no solo para quienes tienen la fortuna de nacer en hospitales bien equipados. Si los estudios confirman seguridad y eficacia, los ensayos clínicos podrían comenzar en pocos años, con el potencial de transformar la respuesta global a una de las lesiones más devastadoras del inicio de la vida.
Every year, roughly two million newborns worldwide experience a catastrophic event in the first moments of life: their brains are starved of oxygen and blood flow during delivery or immediately after. The condition is called neonatal hypoxic-ischemic encephalopathy, and it kills some of these infants outright. Those who survive often face a lifetime of severe neurological disability. For decades, doctors have had almost nothing to offer.
The only treatment available today is therapeutic hypothermia—cooling the baby's body to slow metabolic damage. But it comes with brutal limitations. It only works for full-term infants with moderate to severe cases, and only if administered within the first six hours of life. It requires sophisticated medical infrastructure. In much of the world, where births happen in rural clinics or at home, this treatment is simply not an option. Premature infants, who are already fragile, fall outside the approved window entirely.
A research team at Madrid's Hospital Clínico San Carlos, led by José Martínez Orgado, is pursuing a different path. They are developing an oral formulation of cannabidiol—CBD, the non-intoxicating compound from cannabis—as a potential treatment for neonatal brain injury. The approach is fundamentally different from cooling therapy. Rather than slowing damage, CBD would work to reverse the cascade of cellular destruction that follows oxygen deprivation. The drug would be given within the first 18 hours of life, a wider window than current options allow.
The research team has already demonstrated in animal models that CBD acts as a potent anti-inflammatory and antioxidant agent, two mechanisms that could interrupt the chain reaction of brain damage. Now they are working to develop a formulation suitable for newborns—an oral solution that can be safely administered to infants just hours old. The next phase involves testing the compound in animal models to establish safety and determine appropriate dosing before moving to human trials.
What makes this work potentially transformative is its scope. Unlike therapeutic hypothermia, an oral CBD treatment would not require specialized equipment or highly trained personnel. It could theoretically be given in any setting—a rural health post, a home delivery, a low-resource hospital. It would work for premature infants over 33 weeks of gestation, a population currently excluded from existing therapy. It would be accessible regardless of a family's economic circumstances or where they live.
Martínez Orgado's team is explicit about their ambition: they want a treatment that works for all patients with neonatal hypoxic-ischemic encephalopathy, not just those fortunate enough to be born in well-equipped hospitals in wealthy countries. If the animal studies confirm safety and efficacy, human trials could begin within a few years. Success would not only address one of the most devastating complications of birth but could open doors to treating other neonatal conditions that currently have no medical remedy at all.
The stakes are measured in millions of lives—both the children who might be saved from death and those who might be spared from lifelong disability. The research is still in early stages, but the potential has drawn serious attention from the medical community. What happens in the next few years of testing could reshape how the world responds to one of childhood's cruelest injuries.
Citas Notables
The team aims to develop a treatment applicable to all patients with neonatal hypoxic-ischemic encephalopathy, regardless of socioeconomic circumstances or disease severity— Research team at Hospital Clínico San Carlos
La Conversación del Hearth Otra perspectiva de la historia
Why does the current treatment fail so many babies?
Therapeutic hypothermia is elegant in theory but brutal in practice. You need the right equipment, trained staff, and you have to start within six hours. Most births in the world don't happen in that kind of setting. And premature babies—the ones who need help most—can't even receive it.
So CBD is just a workaround for poor infrastructure?
It's more than that. Even in wealthy hospitals, hypothermia only helps some patients. CBD is designed to actually reverse the damage, not just slow it down. And you can give it over a longer window, to more kinds of babies, anywhere.
How confident are they that this will work in humans?
They've seen it work in animals. The next step is proving it's safe to give orally to newborns. That's the real test—not whether it works, but whether it's safe enough for the most vulnerable patients.
What happens if it fails?
Then we're back where we started. But if it works, you're talking about preventing millions of deaths and disabilities. That's not incremental progress. That's transformative.
How long until we know?
Animal studies first, then human trials if those go well. Probably years. But the timeline matters less than the destination. This could change how we treat not just this condition, but other neonatal diseases we have no answer for.